In this context, CD40L–CD40 signaling may sustain immunosuppression and blocking CD40L–CD40 interaction with antagonistic CD40 antibodies, such as Lucatumumab, may increase the anti-tumor immune response and may be tested in combination with immunotherapy (Byrd et al. 2012). This evidence concerns the gene CD40 and neoplasm.